Clinical Study of Allogeneic Adipovarian Active Protein in the Treatment of Severe Idiopathic Pulmonary Fibrosis
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trail is to study the efficacy and safety of allogeneic
adipocyclical active protein in the treatment of severe idiopathic pulmonary fibrosis.
The main questions it aims to answer are:
1. Efficacy of allogeneic adipromic active protein in the treatment of severe idiopathic
pulmonary fibrosis
2. Safety of allogeneic adipovularic active protein in the treatment of severe idiopathic
pulmonary fibrosis.
A total of 7 participants will be enrolled. Participants will be asked that they will receive
2ml of each nebulized inhalation Cell Free Fat Extract (CEFFE), inhaled every 3 days, for a
total of 7 nebulized inhalation treatments.
The clinical trial was designed using a single-center, self-controlled trial with no control
group and no blinding.
Phase:
Early Phase 1
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University